Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Gynecologic 5Dermatologic 5Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Breast 3Thoracic 2Plasma cell 2Other solid neoplasm 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Neuroblastoma 1

Interventions

Radiotherapy 63Temozolomide 59Magnetic Resonance Spectroscopy 46Carboplatin 40Cyclophosphamide 39Vincristine 35Specimen Handling 28Etoposide 26Cisplatin 26Radiation 22Chemotherapy, Adjuvant 22Filgrastim 20Bevacizumab 20Doxorubicin 18Peripheral Blood Stem Cell Transplantation 17Biopsy 17Vorinostat 16Surgical Procedures, Operative 14Melphalan 13Immunoglobulin G 13Disulfides 13Radiotherapy, Conformal 12Isotretinoin 12Erlotinib Hydrochloride 12X-Rays 11Nivolumab 11Irinotecan 11Carmustine 11aldesleukin 10Topotecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Interleukin-12 Subunit p35 × CNS × Clear all
NCT00054405 2013-04-09

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡